Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age

Sarcopenia Clinical Trial

Official title:

Concurrent Assessment of Skeletal Muscle Mass and Synthesis/Breakdown in Old Age: Defining Diagnostics and the Aetiology of Sarcopenia to Identify "At-risk" Individuals and Appropriate Countermeasures

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04114383
• Other study ID #: Abbeyfield
• Status: Completed
• Start date: June 7, 2016
• Est. completion date: February 2020

Study information

• Verified date: October 2019
• Source: University of Nottingham
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study involves minimally-invasive techniques to measure muscle mass, muscle protein breakdown and synthesis simultaneously in older age.

Description:

Most people will have noticed that with age people become frail. This is principally due to wasting of skeletal muscle known as "sarcopenia". Crucially, sarcopenia is more than just a symptom of weakness and poor functional capacity; it exposes people to an increased risk of falls and fractures, impacting quality of life, independence, health status and ultimately lifespan. Muscles represent the largest organ in the body, making up over 50% of total body weight. Most people know that skeletal muscles are important for movement and to support the skeleton, but not everyone is aware of how important muscles are for whole-body health. For example, muscles represent a vast protein store containing amino acids (the building blocks of protein) which can be broken down in times of fasting, infection and disease in order to provide energy to help other vital organs. Because of the detrimental effects on health, and the associated health costs, sarcopenia is of grave concern. Therefore, there is a significant clinical need to pre-identify at-risk older individuals who have low muscle mass so that they can be offered an intervention (of diet, exercise or drug-based) before they suffer any of the potential problems outlined above. Current techniques for measuring whole-body muscle mass, including MRI and CT are time-consuming, expensive and in huge demand in hospital settings, meaning that muscle wasting conditions such as sarcopenia often go undiagnosed. In this project we propose a potential solution to this problem by developing a diagnostic of sarcopenia that requires only a single drink and subsequent urine collection. In addition, throughout this project we aim to explore the mechanisms underlying muscle wasting by assessing the muscle of those with low and 'normal' muscle mass.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: February 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers of normal body mass index (BMI <35 kg/m2), aged 65-85 years

Exclusion Criteria:

• A BMI > 35 kg/m2

• Active cardiovascular disease:

o angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt, recent cardiac event

• Cerebrovascular disease:

o previous stroke, aneurysm (large vessel or intracranial), epilepsy

• Respiratory disease including:

o pulmonary hypertension, COPD

• Metabolic disease:

o hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, type 1 or 2 diabetes

• Active inflammatory bowel or renal disease

• Malignancy

• Recent steroid treatment (within 6 months) or hormone replacement therapy

• Clotting dysfunction

Related Conditions & MeSH terms

• Atrophy
• Muscle Atrophy
• Muscular Atrophy
• Sarcopenia

Intervention

Other:
• D3-Creatine
30mg D3-Creatine to measure muscle mass
• Deuterium Oxide
D2O provided to measure muscle protein synthesis
• D3-3-methylhistidine
D3-3-methylhistidine is provided to measure muscle protein breakdown

Locations

Country	Name	City	State
United Kingdom	Royal Derby Hospital Medical School	Derby	Derbyshire

Sponsors (2)

Lead Sponsor	Collaborator
University of Nottingham	Abbeyfield

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of D3-Creatine in Urine: 24 hours	To use 30mg of D3-Creatine to measure muscle creatine pool size (g) and whole-body muscle mass (kg) from urine samples taken between 0 and 72 hours. The 0-24 hours collection provides a measure of creatine spillover.	Up to 24 hours
Primary	Measurement of muscle mass using D3-Creatine: 48 hours	To use 30mg of D3-Creatine to measure muscle creatine pool size (g) and whole-body muscle mass (kg) from urine samples taken between 0 and 72 hours. The 0-24 hours collection provides a measure of creatine spillover, spot urines at 48 and 72 hours provide a measurement of the dilution of tracer in urinary creatinine and thus the total muscle creatine pool size.	48 hours
Primary	Measurement of muscle mass using D3-Creatine: 72 hours	To use 30mg of D3-Creatine to measure muscle creatine pool size (g) and whole-body muscle mass (kg) from urine samples taken between 0 and 72 hours. The 0-24 hours collection provides a measure of creatine spillover, spot urines at 48 and 72 hours provide a measurement of the dilution of tracer in urinary creatinine and thus the total muscle creatine pool size.	72 hours
Primary	Rate of dilution of D3-3MH by endogenous unlabelled 3MH release in blood	Using 10mg of D3-3-methylhistidine (D3-3MH) and subsequent multiple blood sampling between 24 and 30h, the rate of dilution of D3-3MH by endogenous unlabelled 3MH release provides a measure of the rate of whole-body muscle protein breakdown.	6 hours (from 24 through to 30 hours)
Primary	Rates of Muscle Protein Synthesis	Using D2O, rate of muscle protein synthesis will be calculated, cumulatively, over 0-3 days by measuring deuterium labelling of alanine into protein from a muscle biopsy at 72 hours.	3 days